AU668908B2 - Multifunctional surface protein of streptococci - Google Patents
Multifunctional surface protein of streptococci Download PDFInfo
- Publication number
- AU668908B2 AU668908B2 AU34351/93A AU3435193A AU668908B2 AU 668908 B2 AU668908 B2 AU 668908B2 AU 34351/93 A AU34351/93 A AU 34351/93A AU 3435193 A AU3435193 A AU 3435193A AU 668908 B2 AU668908 B2 AU 668908B2
- Authority
- AU
- Australia
- Prior art keywords
- sdh
- activity
- streptococci
- protein
- adp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000018697 Membrane Proteins Human genes 0.000 title description 13
- 108010052285 Membrane Proteins Proteins 0.000 title description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 108
- 102000004169 proteins and genes Human genes 0.000 claims description 103
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 50
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 37
- 230000027455 binding Effects 0.000 claims description 31
- 108010067306 Fibronectins Proteins 0.000 claims description 26
- 102000016359 Fibronectins Human genes 0.000 claims description 26
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 25
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 25
- 101710088194 Dehydrogenase Proteins 0.000 claims description 14
- 229960000274 lysozyme Drugs 0.000 claims description 14
- 239000004325 lysozyme Substances 0.000 claims description 14
- 108010014251 Muramidase Proteins 0.000 claims description 13
- 102000016943 Muramidase Human genes 0.000 claims description 13
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 13
- 235000010335 lysozyme Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 102000009062 ADP Ribose Transferases Human genes 0.000 claims description 8
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 101000912181 Arabidopsis thaliana Cysteine synthase, mitochondrial Proteins 0.000 claims 1
- 108010020056 Hydrogenase Proteins 0.000 claims 1
- 101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 97
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 47
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 32
- 229950006238 nadide Drugs 0.000 description 31
- 239000000872 buffer Substances 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 18
- 238000001262 western blot Methods 0.000 description 17
- 239000012528 membrane Substances 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 108060008487 Myosin Proteins 0.000 description 11
- 102000003505 Myosin Human genes 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000005730 ADP ribosylation Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 9
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 6
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 6
- 108010034119 Myosin Subfragments Proteins 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 206010061372 Streptococcal infection Diseases 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 5
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- -1 dioxetane anion Chemical class 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 4
- PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000010217 densitometric analysis Methods 0.000 description 4
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229940083618 sodium nitroprusside Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 102000005937 Tropomyosin Human genes 0.000 description 3
- 108010030743 Tropomyosin Proteins 0.000 description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000698776 Duma Species 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101001061354 Gallus gallus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000047486 human GAPDH Human genes 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108010009719 mutanolysin Proteins 0.000 description 2
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000020236 ADP-ribosylarginine hydrolase Human genes 0.000 description 1
- 108010079768 ADP-ribosylarginine hydrolase Proteins 0.000 description 1
- 102220510810 APC membrane recruitment protein 1_F90A_mutation Human genes 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 101710108485 Envelope phospholipase F13 Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- WPTDJKDGICUFCP-XUXIUFHCSA-N Met-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCSC)N WPTDJKDGICUFCP-XUXIUFHCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- CJAHQEZWDZNSJO-KKUMJFAQSA-N Phe-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CJAHQEZWDZNSJO-KKUMJFAQSA-N 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 241000791420 Plica Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- KQHKSGRIBYJYFX-UHFFFAOYSA-J Ponceau S Chemical compound [Na+].[Na+].[Na+].[Na+].Oc1c(cc2cc(ccc2c1N=Nc1ccc(cc1S([O-])(=O)=O)N=Nc1ccc(cc1)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O KQHKSGRIBYJYFX-UHFFFAOYSA-J 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010023364 glycyl-histidyl-arginine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108091005592 methylated proteins Proteins 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- TYQCGWOGNUOQAR-ZDUSSCGKSA-N n-[(3s)-1-chloro-5-methyl-2-oxohexan-3-yl]-4-methylbenzenesulfonamide Chemical compound CC(C)C[C@@H](C(=O)CCl)NS(=O)(=O)C1=CC=C(C)C=C1 TYQCGWOGNUOQAR-ZDUSSCGKSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102220037654 rs587780327 Human genes 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 108010010318 streptococcal M protein Proteins 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01009—Glyceraldehyde-3-phosphate dehydrogenase (NADP+) (1.2.1.9)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Description
OPI DATE 03/08/93 AOJP DATE 14/10/93 APPLN. ID 34351/93 PCT NUMBER PCT/US93/00082 AU933435 1 IN CMNf I 1UINIAL AI'PLICA I ION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCI) (51) International Patent Classification 5 (11) International Publication Number: WO 93/14198 C12N 9/02, A61K 39/09 Al C12P 21/02 (43) International Publication Date: 22 July 1993 (22.07.93) (21) International Application Number: PCT/US93/00082 (22) International Filing Date Priority data: 07/818,170 07/913,732 Parent Application or Gi (63) Related by Continua us Filed on 7 January 1993 (07.01.93) 8 January 1992 (08.0 1.92) 15 July 1992 (15.07.92) 07/9 13,732 (CIP) 15 July 1992 (15.07.92) (72) Inventors; and Inventors/Applicants (for US only') FISCHETTI, Vincent, A. [UJS/US]; 440 Joan Cou rt, West Hempstead, NY 11552 PANCHOLI, Vijaykumar [US/US]; 220 East 70th Street #8C, New York, NY 10021 (US).
(74) Agent: BURKE, Henry, Wyatt, Gerber, Burke and Badie, 645 Madison Avenue 5th Floor, New York, NY 10022 (US).
(81) Designated States: AU, CA, CZ, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Published With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
668 P1,44 (71) Applicant (for all designated States except US): THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021 (US).
(54)Title: MULTIFUNCTIONAL SURFACE PROTEIN OF STREPTOCOCCI Iis 30 39 VVKVG IN GFGRI GRLAF RRIQON IEG VEVT AI/P NDLT/A D PN SDH VVKVGINGFGRIGRLAFR BStGAP MA KVGINGFGRIGRNVFR ECOGAP MTIKVGINGFGRIGRI VFR HumGAPMGK KVGVNGFGRIGRLVTR chkGAP VKVGINGFGRIG -VTR SmP37 MSR LKVGINGFGRIGR VLR ZmOGAP MAVK AIN GFGRIGRLA R RMN I EG V AALKNPD II AAJRSD
I.
A ISGI( V 0AAVLSGK V AAF LKNTVI
SIMILARITY
A.A. RESIDUE 39 i8 39 E INDLT NM E VAHNDZL NAD 83.3% 56% EIVAIND DY 77.8% 56% DIVAINDPFIDLN 83.3% 54%Il QVV AI NDPFI DLN 77.8% 51% DVVS DPFIDLE 77.8% 46% AHL S R P D S G LELVT IN DLGS V 83.3% 41% (57) Abstract A novel streptococcal surface protein principally characterized by fibronectin and lysozyme binding activity, but also having glyceraidehyde-3-phosphate dehydrogenase activity, ADP-ribosylating activity and ADP-ribosyl transferase activity are described. It is particularly useful for the preparation of vaccines to protect against streptococcal infections.
now WO93/14198 PCT/US93/00082 MULTIFUNCTIONAL SURFACE PROTEIN OF STREPTOCOCCI This invention was made with government support under Grant Number AI-11822 awarded by the National Institutes of Health. The Government has certain rights in the invention.
RELATED APPLICATION This application is a continuation in part of commonly owned and copending application serial number 07/913,732 filed July 15, 1992 which is, in turn, a continuation of application serial number 07/818,170 filed January 8, 1992. The latter application is now abandoned.
This invention relates to a surface protein of streptococci which is involved in early colonization of the pharyngeal mucosa. More specifically, it relates to a multifunctional protein which is on the surface of streptococci, including pathogenic streptococci, such as Streptococcus pyogenes and is particularly characterized by its ability to bind fibronectin, lysozyme, and the cyclosketal proteins myosin and actin as well as by its enzyme activity, specifically dose dependent dehydrogenase activity with glyceraldehyde-3-phosphate (GADPH). The molecule also functions as an ADPribosylating enzyme and as an ADP-ribosyl transferase.
It is concerned also with therapeutic compositions and uses of the surface protein including, for example vaccines prepared from the whole protein and segments thereof, particularly conserved segments having activity similar to that of the protein.
I_ 1 SWO 93/14198 PCT/US93/00082 2 BACKGROUND OF THE INVENTION Mammalian diseases, especially human diseases caused by streptococcal infection with bacteria such as Streptococcus pyogenes are a significant health problem.
In the United States alone, 25 to 35 million cases of group A streptococcal infections, which primarily afflict school age children are reported annually The high incidence and potential severity of streptococcal infections provide impetus for development of an effective and safe vaccine to prevent streptococcal related infections.
It has now been discovered that there is a streptococcal surface dehydrogenase (SDH} protein on the surface of streptococci from several serological groups such as group A type 6 streptococci which has both enzymatic activity and a binding capacity for a variety of proteins. In the earlier applications in this series, this surface protein was referred to as MF6, that being the laboratory code designation assigned to it when it was initially isolated, purified and characterized. It is now referred to as SDH since one of its principal characteristics is that it is Streptococcal Surface Dehydrogenase. More specifically, it is a member of the class of proteins which manifest glyceraldehyde-3phosphate dehydrogenase (GAPDH) activity.
GAPDH proteins, as the name implies, are a class of dehydrogenase enzymes intimately involved in mammalian physiological reactions. Generally, members of the class are found in the cytoplasm, but some have been found associated with membranes and cellular cyclosketal structures of eukaryotes. The glycolytic enzyme of this r i WO 93/14198 PCT/US93/00082 :3 invention is believed to be unique fn that it is a surface protein of prokaryotes. No other such GAPDH protein has previously been described.
The GAPDH protein of this invention has some structural characteristics similar to other proteins of the GAPDH family. For example, over 80% of the NH terminal 18 of 39 amino acids are identical to the GAPDH family of enzymes. However, it differs in many other respects, as will be explained hereinafter. It is, therefore, a novel product which has not heretofore been isolated and characterized.
A detailed characterization of purified SDH has disclosed that its native conformation is probably a tetramer with a molecular weight of about 156 kDa. The molecular weight of the protein by mass spectrometric analysis is about 35.8 kDa. By SDS PAGE, it is about 39.2 kDa.
The protein has been identified on the surface of Groups A, B, C, E, G, H and L streptococci utilizing affinity purified anti-SDH antibodies. The protein exhibited a dose dependent dehydrogenase activity on glyceraldehyde-3-phosphate in the presence of beta nicotinamide adenine dinucleotide (NAD). The multifunctional activity of SDH was revealed by its ability to bind fibronectin and lysozyme as well as the cytoskeletal proteins myosin and actin. The binding Sactivity of SDH to myosin was found to be localized to the globular heavy meromyosin domain. SDH did not bind to streptococcal M protein, tropomyosin or the coiledcoil domain of myosin. The multiple binding capacity of SDH especially in connection with cycloskeletal proteins, in conjunction with its GAPDH activity indicates a role I n; i I I WO93/14198 PCr/US93/00082 in the colonization, internalization and the subsequent proliferation of streptococci. Trypsin treatment of whole streptococci resulted in a marked reduction in their reactivity to SDH antibodies. The inability to 3 remove SDH from the streptococcal surface after washing in 2 M NaCl or 2% SDS indicates that the protein is not peripherally associated but tightly bound to the cell.
These data all indicate that the protein is a surface GAPDH molecule on the streptococcal cell.
The novel SDH is obtained by solubilizing the selected streptococcus with lysin to produce a mixture containing SDH. The SDH may be isolated from the mixture by any of a number of convenient methods known to the skilled artisan including the method illustrated below.
It may also be produced by transforming an organism such as E. coli with an appropriate gene so that the E.
coli will express SDH.
The following abbreviations are employed in the description of this invention: NAD: beta nicotinamide adenine dinucleotide PVDF: polyvinylidine difluoride EDTA: Eyhylenediamine tetra acetic acid PMSF: Paradimethyl sulfonyl fluoride TLCK: N-p-tosyl-L-lysine chloro-methyl ketone SDS: Sodium dodecyl sulfate Mono Q FPLC: Mono Q(Trade Name) Fast protein liquid chromatography Superose 12 FPLC: Superose-12(Trade Name) Fast protein liquid chromatography TSK-Phenyl HPLC: TSK-Phenyl (Trade Name) high performance/pressure liquid WO 93/14198 PCT/US93/00082 chromatography NADH: beta-nicotinamide adeninedinucleotide, reduced ELISA: Enzyme linked immunosorbent assay ELIDA: Trade name of Physica Inc.
Sephadex G-25 PD-10: G-25 PD-10: trade name of Pharmacia-LKB Inc.
HEPES: (N-[2-hydroxyethyl]piperizine-N'-[2-ethansulfonic acid]) RGDS: Arginine-Glycine-Aspartic acid-Serine (Arg-Gly- Asp-Ser) G-3-P: Glyceraldehyde-3-phosphate GAPDH: Glyceraldehyde-3-phosphate dehydrogenase THE FIGURES There follows a description of the figures.
SDH protein from M6 streptococci. Lane a: Lysin extract of D471 streptococci. Lane b: Precipitate of (NH4)204 saturation of the lysin extract. Lane c: Precipitate of 85% (NH,) 2
SO
4 saturation of the supernatant after 65% precipitation. Lane d: Pooled Mono Q fractions at 0.28 M gradient elution. Lane e: Partially purified SDH from the Superose 12 column. Lane f: Purified SDH from Phenyl TSK column. Arrow marks on lanes a and b at 50 kDa indicate the position of M protein. Prestained marker protein mixture with molecular mass as indicated on the left margin. 200 kDa:Myosin(H-chain), 97.4 kDa: Phosphorylase b, 68 kDa:bovine serum albumin, 43 kDa: ovalbumin, 29 kDa: carbonic anhydrase, 18.0 kDa: lactoglobulin, 14.3 kDa: egg-white lysozyme.
"i WO 93/14198 PCT/US93/00082 6 Fig. 2: The NH 2 -terminal sequence of SDH.
Comparison of the NH2-terminal amino acid sequence of SHD with the amino acid sequences of the known GAPDH molecules obtained frm the translated Genbank database.
BstGAP- Bacillus stearothermophilus GAPDH, EcoGAP- Escherichia coli GAPDH, HumGAP- human GAPDH, GAPDH, ChkGAP- Chicken GAPDH, SmP37- Schistosomia mansoni 37 kDa protein (GAPDH) ZmbGAP- Zymomonas mobilis GAPDH.
Numbers on the right side of the figure indicate the percentage similarity of SDH with other GAPDH molecules with residues 1-18 and 1-39. The gap(-) between the 14th and 15th residue of the chicken GAPDH sequence was introduced to maximize homology.
Fig. 3: Lineweaver-Burk's double reciprocal kinetic analysis of GAPDH activity of SHD. 25 ug of SDH was assayed as function of G-3-P in the presence of NAD (100uM) in triethanolamine-phosphate-EDTA-DTT buffer at pH 8.6. The Km for G-3-P was estimated to be 1.33 uM, -3 1 Vmax: 0.487 X 10 3 M NADH min- intercept Y axis (1/Vmax): 2.05 and slope (Km/Vmax): 2.73. The inset shows the analysis based on Michaelis-Menten. Km: 1.22 mM and Vmax:0.466 X 10 3 M NADH min 1 Lineweaver- Burk's double reciprocal kinetic analysis of GAPDH activity of the 39 kDa protein. 25 ug of SDH was assayed as a function of NAD in the presence of G-3-P (2 mM) in the buffer system as described in The Km for NAD was estimated to be 156.7 uM, Vmax:0.459 X 10 3 M NADH min 1 Intercept on Y axis(l/Vmax) 2.18, and slope (Km/Vmax) 341.74. Km for NAD by the method of Michaelis-Menten as shown in the inset was estimated to be 148.86 uM and Vmax: 0.445 X 10 M NADH min 1 i WO 93/14198 PCT/US93/00082 7 Fig. 4: Coomassie Blue stain of SDS-gel and (B) Western-blot analysis of SDH with affinity purified anti-SDH antibodies suggesting a multimeric structure for the SDH molecule. Lanes a and d: Crude lysin extract.
Lanes b and e: Purified SDH. Lanes c and f: Unboiled purified SDH in sample buffer withort SDS and saturated wit NAD. Arrow mark indicates the position of a molecule of the size consistant with a tetrameric form of SDH. MW markers are indicated on the left margin (Details on each marker-see Fig. i).
Fig. 5: Dot blot immunoanalysis to locate SDH on the streptococcal surface. The assay determines the extent of reactivity of affinity purified anti-SDH antibodies to surface exposed protein before and after 2% SDS, 2M NaCl and trypsin treatments. Dot blots were treated with LumiPhos-530 substrate (41) and developed on X-ray film. Densitometric reading of the image obtained on the X-ray film was expressed as an optical density in terms of arbitrary units measured on an image analyzer using the Dumas program (Drexel University, Philadelphia, USA). An internal linear standard curve for the optical density 0.008 to 1.333 was obtained for final densitometric analysis of the dot blot. Each bar representes the mean o: four to eight separate readings
S.D.
Fig. 6: GAPDH activity of whole streptococci. (a) The GAPDH activity was observed at 340 mn of whole M6 streptococci by determining the conversion of NAD to NADH in the presence of G-3-P. Details of the buffer system is described in materials and methods. Activity of trypsinized M6 streptococci. Inhibition of enzyme WO 93/14198 PCT/US93/00082 8 activity of affinity purified anti-SDH antibodies (1:30 of 0.5 mg/ml for 3 hr at room temperature). Each bar represent the mean of three separate readings S.D.
Fig. 7: Western-blot analysis of lysin extract of various streptococcal M types with affinity purfied anti-SDH antibodies at a 1:2000 dilution of 0.5 mg/ml stock. Purified SDH and an M negative (M streptococci are also incuded in the analysis. Western-blot analysis of mutanolysin extract of various grouping strains of streptococci ucing anti-SDH antibodies as described in Fig. 8: Competition kinetic enzyme-linked immunosorbent assays (kELISA) with immobilized SDH.
Commercially available purified GAPDH from B.
stearothermophilus, human erythrocytes and rabbit skeletal muscle were used to compete for the binding of affinity purified anti-SDH antibodies (1:1000 dilution of mg/ml stock). Each cv ve represents the mean of three separate experiments with less than 5% standard deviaiton (not shown). Inset shows the Western blot of the reactivity of affinity purified anti-SDH antibodies with streptococcal SDH and GAPDHs of bacterial stearothermophilus), rabbit skeletal muscle and human erythrocytes.
Fig. 9: Binding of 1 I-SDH to cytoskeletal proteins. Coomassie Blue stained SDS-PAGE gel containing 5 ug protein of various cytoskeletal proteins, lysozyme and M6 protein Lane a: rabbit skeletal myosin. Lane b: heaving meromyosin. Lane c: light i 30 meromyosin. Lane d: actin. Lane e: M6 protein. Lane f: S-2 fragment of heavy meromyosin. Lane g: egg white i lysozyme. autoradiograph of proteins in a duplicate I 4 WO 93/14198 PCT/US93/00082 gel after transfer onto nitrocellulose and incubation with the 125 I-SDH. The proteins in each lane are as described in Fig. MW markers on the left margin (Detail of each marker see Fig. 1).
Fig. 10Z Binding activity of SDH to fibronectin.
Coomassie stain of an SDS gel containing 5 ug of SDH and BSA. Western-blot analysis of a duplicate gel showing the binding of fibronectin followed by antifibronectin to the SDH molecule. Autoradiograph of a similar Western blot showing the binding of fibronectin to the SDH protein. Lanes a, c e SDH.
Lanes b, d, f BSA.
Fig. 11: ADP-ribosylation of SDH. Purified SDH (lanes 1, 5 and crude streptococcal cell wall extract (lanes 2, 6 and 10), cytoplasm (lanes 3, 7 and 11) and membrane (lanes 4, 8 and 12) fractions were incubated with [32 P]NAD in ADPR buffer. The proteins were then separated on a 12% SDS gel and stained with Coomassie blue. Western blot analysis of a duplicate gel reacted with affinity purified anti-SDH antibodies and autoradiography of a similar Western blot. MW marker is indicated on the left side.
Fig. 12: ADP-ribosyl transferase activity of SDH.
SDH and various bindig proteins (2740) were incubated 32 together in the presence of P]NAD. Protein mixtures were precipitated, washed and resolved on 12% SDS-PAGE and stained with Coomassie blue and a duplicate gel was dried and autoradiographed. SDH was incubated with actin (lanes, 1 and chicken egg white Lysozyme (lanes, 2 and S-i fragment of myosin (lanes, 3 and 8), fibronectin (lanes, 4 and and plasmin (lanes, 5 and MW markers are indicated on the left side.
WO 93/14198 PCT/US93/00082 The following Materials and Methods section is provided for convenience and ease of understanding the invention.
MATERIALS AND METHODS Materials: Human fibronectin was obtained from Boehringer Mannheim. Goat anti-human fibronectin and affinity purified rabbit anti-goat IgG coupled to alkaline phosphatase were obtained from Sigma. Pre-stained molecular weight standards were purchased from Bethesda Research Laboratories. PVDF membrane "Immobilon-P" was 125 from Millipore. Na I was from New England Nuclear. All other chemicals and reagents unless otherwise indicated were purchased from Sigma.
Bacteria: Bacteria. Group A 6-hemolytic streptococcal strains of various M types and standard strains used for streptococcal grouping were from The Rockefeller University culture collection (New York, NY) and are listed as follows: M2(D626), M4(D896), M6(D471), M24(CS24), M29(D23), M41(C101/103/4), M57(A995), M58(D774), M60(D398), M (T28/51/4); group A, J17A4 (an M- strain); group A variant, A486var; group B, 090R; group C, C74; group D, D76; group E, K131; group F, F68C; group G, D166B; group H, F90A; group L, D167B; and group N, C559.
I h 1 WO 93/14198 PCT/US93/00082 11 Lysin extraction and location of SDH protein: A crude extract containing the major surface proteins was prepared using the procedure of lysin extraction to remove the streptococcal cell wall as described before Essentially, bacteria washed in mM sodium acetate buffer, pH 5.5 were suspended in the same buffer containing 30% raffinose and 5 MM EDTA.
Lysin is added to the suspension (1:100 dil; 360 Units) and incubated for 90 min at 37 C with end-to-end slow rotation. The resulting protoplasts sedimented at 15,000 X g for 30 min in a Sorvall centrifuge. The supernatant was saved, dialyzed against 25 mM Tris/HC1, pH 8.5,5mM EDTA, concetrated on Amicon PM-10 membrane (Amicon Corp) and used for further purification.
After lysin extraction, the pelleted protoplasts were resuspended and lysed in hypotonic buffer (2 MM sodium acetate, pH 5.5, containing 2 mM PMSF, 1 MM TLCK, MM MgC1 2 and 10 ug/ml DNAse) followed by three freeze/thaw cycles. The membranes were sedimented at 100,000 x g for 45 min at 4°C. The membrane pellet and cytoplasmic extract in the supernatant were analyzed wits Coomassie blue stain after separation on SDS gel.
Membranes were further treated with 1.5 M sodium chloride or 100 mM sodium carbonate, pH 11.3 to determine the nature of association of SDH protein with the membrane.
To determine whether this protein is surface exposed, lysin extraction of trypsinized bacteria was carried out as described earlier Briefly, washed bacteria were suspended in 100 mM NH HCO 3 and digested with trypsin (250 ug/ml) at 37°C for 3 hr, after which the trypsin was inactivated by the addition of soybean trypsin inhibitor (200 ug/ml). Lysin extracts of WO 93/14198 PCT/US93/00082 trypsinized and control non-trypsinized bacteria were compared for the loss or reduction in the size of SDH protein.
Purification of SDH: Lysin extraction was used as the starting material for the purification of the SDH. The dialyzed, concentrated, lysin extract was precipitated at saturation of ammonium sulfate at 4 C. The precipitates were centrifuged at 6,000 X g for 20 min and the supernatant was brought to 85% saturation of ammonium sulfate. The resulting precipitate was dialyzed against mM Tris/HCl buffer pH 8.5, 5 mM EDTA and passed over to Mono Q FPLC column (Pharmacia LKB Biotechnology Inc.) equilibrated with the same dialyzing buffer. After the column was washed with 5 column volumes of starting buffer, bound proteins were eluted with a 50 ml linear NaCL gradient from 0 to 300 mM. Fractions containing SDH were pooled and dialyzed against the 35 mM Tris/HCl/EDTA buffer and rechromatographed on the Mono Q column.
Fractions containing SDH were then pooled, and concentrated to a volume 1.0 ml on Centricon concentrator (cutoff mw 10,000 kDa). The concentrated sample was applied to a Superose 12 FPLC column (Pharmacia LKB Inc) pre-equilibrated with 50 mM Tris/HCl pH 8.5 containing 0.3 M NaCl and 5 mM EDTA. Fractions containing SDH protein were pooled, dialyzed against 0.025 M Tris/HC1 buffer pH 8.5 containing 1.0 M (NH4)2SO4 and applied to a TSK-phenyl HPLC column (Bio-Rad Laboratories, Richmond CA) preequilibrated in the same buffer. Theprotein was eluted by a decreasing linear gradient of (NH 4 2 S0 4 from 1.0 M to 0.0 M. The purity of the final product was determined by Coomasie blue stain of the purified protein on SDS gel and by the analytical I- -i WO 93/14198 PCI/US93/00082 27 Bindin.f fibronectin to the SDH protein: WO 93/14198 PCrUS93/00082 13 procedures. Purified material was stored at 4°C after dialyzing against 0.025 M Tris/HCl pH 8.5 for various protein binding experiments or at -70°C for longer storage.
Analytical Procedures (NH 2 -terminal sequence and amino acid composition): NH2-terminal amino acid sequence was determined according to the method of Matsudaira et al Briefly, the purified SDH was separated on a preelectrophoresed 10% acrylamide-SDS gel under nondenaturing condition and then transferred to PVDF Immobilon-P filter pre-wetted in methanol. Protein was visualized by 0.05% Coomassie blue in 50:40 methanol, water, acetic acid solvent mixture. The blots were destained in methanol: water: acetic acid (50:40:10).
The portion of the membrane containing the SDH band was excised and subjected to automated Edman degradation on an Applied Biosystem model A470 sequenator. Each band contained about 2-3 ug protein as determined by BCI protein estimation method (Pierce). For amino acid composition, the PVDF membrane containing the SDH was stained with 0.1% Ponceau-S (Sigma) in 1% acetic acid.
The section of membrane containing the protein band was excised and destained with water. This section of membrane was hydrolyzed in 6N HCl/phenol at 110°C for 22 hr. Amino acids were separated on Waters Novapek C8 column analyzed with Waters Maxima software, 510 pump and 490 detector. Cysteine content was analyzed also from the PVDF bound carboxyamide methylated protein as described by Crestfield All analyses were performed by Protein Biotechnology Facility of the Rockefeller University.
i "K
N
SWO 93/14198 PCT/US93/00082 ,14 Molecular Mass Determination: Molecular mass of the purified protein was determined in the department of Mass Spectrometry and Gas Phase ion chemistry of The Rockefeller University using the modified method of matrix-assisted laser desorption technique Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Activity: GAPDH assay was carried out according to the method originally described by Ferdinand with a minor modifications. Since GAPDH catalyzes the oxidative phosphorylation of D-G-3-P to form 1,3-diphosphoglycerate in the present of NAD and inorganic phosphate, the assay solution was made of triethanolamine (40 mM), Na 2
HPO
4 mM) and EDTA (5 mM). Disposable semi-micro 1.5 ml capacity spectrophotometer cuvette (VWR) contained 7ul G-3-P (Sigma, 49 mg/ml), 100 uM NAD (Boehringer Mannheim) and assay buffer to a final volume of 1.0 ml after the addition of enzyme source with pH of the mixture being 8.6. Different concentrations of SDH were used to plot the standard curve for the absorbance at 340 nm per minute as a measure of conversion of NAD to NADH using Spectronic 3000 spectrophotometer (Milton Roy).
Enzyme Kinetics: Kinetics of enzymatic reaction of SDH were made with /i varying concentrations of NAD and a fixed concentration of G-3-P and vice versa to determine respectively the Km and Vmax for NAD and G-3-P. The results were recorded as rate analysis of NADH release at every half second for a period of 1 min at 340 nm. The molar extinction l-j_ SWO 93/14198 1 5 PC/US93/00082 coefficient of NADH 6.22 X 103 was used to convert absorbance (340 nm)/min to NADH M/min. The kinetic coefficient were estimated from the secondary plots of intercept of primary Lineweaver-Burke plots with respect to each substrate. The specific activity of the enzyme (units/mg) was measured using the equation: Sp activity v(l+m/S)NA(1+Km/S) 3_pwhere v u moles NADH/min/mg of enzyme.
Specific activity of GAPDH activity for SDH was measured in the lysin extract, ammonium sulphate precipitate and pooled fraction at various purification stages.
Rabbit Immunization and affinity purification of immune sera: New Zealand white rabbits were immunized subcutaneously with 200 ug of purified SDH emulsified in Freund's complete adjuvant at multiple sites.
Rabbits were boosted once with 200 ug of this protein in Freund's incomplete adjuvant All rabbits were bled 3 weeks after the first and 10 days after the second immunization. All sera were filter sterilized and stored at 4 C.
To purify SDH specific antibodies from the polyclonal sera, 2.0 mg of purified SDH was linked covalently with free amino group of gluteraldehydeactivated affinity adsorbent as described before Anti-SDH rabbit sera (2-3 ml) was adsorbed to and eluted from the SDH-beads column, dialyzed, concentrated and stored as described before These antibodies were further purified on Protein A column (Pharmacia LKB) 1 i 1 s i
I
WO 93/14198 PCT/US93/00082 essentially using the same buffer described above The monospecificity of anti-SDH was first checked on Western blot as described above.
Dot-Blot Immunoassay to determine location of SDH: The surface location of SDH was determined with the monospecific antibodies using a bacterial dot-blot immunoassay as previously described Essentially, an overnight culture of strain D471 was adjusted to OD 650 nm 1.0 with 50 mM Tris/HCl buffer, pH 8.5. Aliquots of this suspension were centrifuged and resuspended to the same volume of buffer containing either 2 M NaCI or 2% SDS, and rotated at room temperature for 1 h, centrifuged, and the respective supernatants were saved.
After washing, the pellets were again adjusted to OD 650 nm 1.0 with 50 mM Tris/HCl buffer, pH 8.5. In a separate experiment, the bacterial suspension in the Tris/HC1 buffer was centrifuged, and the bacteria were suspended in 100 mM NH HCO to OD6 n 1.0 and treated with 4 3 650 nm trypsin (250 ug/ml) for 3 h at 37 C. Trypsin activity was inhibited with trypsin inhibitor as described above, and the bacteria were pelleted and resuspended in the Tris/HCl buffer to OD 0 nm 1.0 50 ul of each bacterial suspension was transferred to nitrocellulose paper using dot-blot assembly (Bio-Rad Laboratories, Richmond, CA).
Reactivity of surface-exposed epitopes of the 39-kD protein was determined using affinity-purified anti-SDH protein antibodies (1:1,000 dilution of 0.5 mg/ml stock).
For densitometric analysis of the dot blot, a duplicate I! blot was developed with Lumi-Phos T530 (Adamantyl-1,2dioxetane phenylphosphate; Lumigen Inc., Detroit, MI), which undergoes enzyme (alkaline phosphatase)-catalyzed dephosphorylation to form a dioxetane anion that is converted ultimately into an excited state of the methyl
V
.4 WO 93/14198 PCT/US93/00082 17 meta-oxybenzoate anion, the light emitter. The developer was then drained off, and the wet blot wrapped in Saran Wrap was exposed to x-ray film for 20 min and developed using conventional procedures. Densitometric analysis of each spot on the x-ray film was carried out on an image analyzer using the conventional procedures.
Densitometric analysis of each spot on the x-ray film was caried out on an image analyzer using the Dumas program (Drexel University, Philadelphia, PA) interfaced with IBM computer.
GAPDH enzymatic activity of intact SDH protein on whole streptococci: A whole cell assay was developed to determine whether SDH on the surface of streptococci serves as an active GAPDH enzyme. Different concentrations of trypsinized and non-trypsinized streptococci were incubated with and without G-3-P in presence of NAD in triethanolamine-phosphate-EDTA-DTT buffer as described above in a final volume of 1.0 ml for a period of 2 min at room temperature and centrifuged to pellet out the bacteria. The supernatants were analyzed for the conversion of NAD to NADH by recording absorbance at 340 nm. This enzymatic activity was also determined on streptococci preincubated with 1:50 dilution (1 mg/ml) of purified anti-SDH antibodies as prepared above to determine specific inhibition of enzymatic activity.
Polyacrylamide gel electrophoresis and Western blotting: Electrophoresis, Western blotting of lysin extraction and protein samples at different purification stages were carried out as described earlier Specific proteins bound to the nitrocellulose membrane
U,
mc I- WO 93/14198 PCr/US93/00082 18 were probed and visualized with affinity purified anti- SDH antibodies (1:2000, 0.5 mg/ml) as described previously Presence of SDH on heterologous streptococcal M serotypes: Lysin extracts of M serotypes 2, 4, 5, 6, 24, 29, 41, 57, 58, 60, and M were prepared as described The muralytic enzyme mutanolysin (20 ug/ml; sigma Chemical Co.) was used to prepare cell wall extracts of each grouping strain suspended in 50 mM Tris/HCl buffer, pH 6.8, containing 5 mM EDTA, 5 mM MgC12, and raffinose, and incubated at 37°C for 60 min under constant end-to-end rotation. Proteins in all the extracts were separated on SDS-PAGE and transferred to nitrocellulose. The blots were probed with affinitypurified anti-SDH protein antibodies as described above.
Relationship of GAPHDs from bacterial and mammalian origins with SDH: The cross reactivity of GAPDHs isolated from rabbit skeletal muscle, human erythrocytes and B.stearothermophilus were determined both on Western blot and competitive ELISA as described below.
ELISA and Competitive inhibition: 1 j Affinity purified antibodies were adjusted to a dilution that gave an ELISA reading of 1.0 at 405 nm after 60 min. ELISA was performed following standard procedures except that ELISA plates were coated with 100 ul/well of 1 ug/ml SDH for 3 hr at 37°C followed by overnight at 4°C.
i' 1( 'if Ti mm 06- WO 93/14198 PCT/US93/00082 19 Competition of GAPDH from different bacterial as well as mammalian origin containing cross reactive epitopes for the binding of Anti-SDH antibodies was performed as described previously Briefly, ELISA plates were coated as described above with SDH. Optimum dilution of affinity purified antibodies as determined above was used. Competing GAPDH were serially diluted in antibody diluting buffer containing 0.05% Brij-35 pH 7.4 at decreasing molar excess relative to SDH starting with 100 X molar excess. Anti-SDH antibodies were then added in each well and the plates were processed and finally developed and binding of these proteins was determined by kinetic ELISA as described (11) using ELIDA microtitre plate reader Physics Inc. (20) at 405 nm.
Radioiodination of Proteins: 125 SDH was labeled with 125I by the chloramine-T method using Iodobeads (Pierce Chemical The labeled protein was separated from free iodine by filtration over a column of Sephadex G-25 (PD-10, Pharmacia LKB Biotech Inc) and collected in 10 mM HEPES buffer saline pH 7.4 containing 10 mM MgCl 2 2 mM CaC1 2 50 mM KC1 and 150 mM NaC1. The labeled protein was stored at -20°C in aliquots containing 0.02% NaN 3 Fibronectin and plasmin were labeled essentially by the same method. The specific activities of SDH, fibronectin and plasmin were, respectively, 2X105, 1.0X106 and 1.21X106 CPM/mg.
Binding Studies: The Binding activity of SDH and fibronectin was determined by the use of radioactive proteins. Egg white-lysozyme and/or cytoskeletal proteins (myosin, heavy meromyosin (HMM), light chain myosin (LMM), i1* 1 i SWO93/14198 PCT/US93/00082 tropomyosin, and actin) all of which obtained from Sigma, were electrophoresed on 10% SDS-PAGE gels and electroblotted on nitrocellulose paper. The blots were blocked in 10 mM HEPES buffer containing 15 mM NaC1, Tween-20, 0.04% NaN 3 and 0.5% BSA pH 7.4 for 2-3 hr at 3 room temperature and probed for 3-4 hr at room 125 temperature in the same buffer containing I- 125 5 fibronectin, 5I-plasmin at 3X105CPM/ml. The probed blots were then washed 3-4 times with blocking buffer.
Autoradiography were prepared by exposing the dried nitrocellulose blots to Kodak Blue Brand film with an intensifying screen for 36-48 hour at -70 C.
Lysin fractionation of Streptococci for ribosylation study: An overnight culture of streptococci was washed and the cell wall was digested using the amidase enzyme lysin in 30% raffinose at pH 6.1 as described After lysin extraction, which represents the cell wall fraction of the streptococci, the resulting protoplasts were further fractionated into cytoplasm and membrane after lyisng in a hypotonic buffer containing 10 mM MgCl 2 and DNAse (250 ug/ml) as described Membranes were then separated from the cytoplasmic fraction by ultracentrifugation (100,00 X g, 45 minn, ADP-Ribosylation of SDH: The ADP-ribosylation of SDH was performed as described (15) with slight modification. Briefly, the standard reaction mixture (0.2 ml) contained 100 mM Tris/HCl at pH 7.4, 10 mM dithiothreitol, 1 mM NADP, mM thymidine (ADPR buffer). After the addition of 10 uM [alpha- 32 P]NAD and 20 ug of purified SDH, the reaction C i t WO 93/14198 PCT/US93/00082 21 mixture was incubated for 1 hour at 37°C. The reaction was then stopped by the addition of 50 ul of 100% (w/v) chilled trichloroacetic acid (TCA), and allowed to stand for 30 minutes on ice after which time the precipitated proteins were separated by centrifugation (16,000 X g, minutes at The protein pellet was washed in absolute alcohol containing 1% of 5 M sodium acetate and dried in a Speedvac (Savant) to remove remaining TCA.
The dried precipitates were dissolved in 50 ul of sample buffer and then subjected to SDS-PAGE (12% polyacrylamide) as described The gel was dried, and autoradiograms were made with Kodax X-omat film using an intensifying screen at -80 0
C.
GAPDH Activity of ADP-ribosylated SDH: The GAPDH activity of purified SDH and the ADPribosylated SDH was measured by the method originally described by Ferdinand and modified as described Briefly, the reaction was performed in a final volume of 1 ml containing 800-850 ul of buffer (40 mM triethanolamine, 50 mM Na 2
HPO
4 5 mM EDTA, pH 8.6), 100 uM NAD and the enzyme source (ADP-ribosylated and non-ADP-ribosylated SDH, 5 ug) dispensed in a 1.5 ml capacity microcuvette. The reaction was initiated with the addition of 7 ul glyceraldehyde (49 mg/ml).
Absorbance at A340 nm showing the conversion of NAD to NADH was recorded over a period of 2 min.
Effect of Sodium Nitroprusside on the ADP-Ribosylation of SDH: Sodium nitroprusside was freshly diluted in ADPR buffer (200 ul) to a final concentration of 2 mM and preincubated for 2 minutes at room temperature before the 1 WO 93/14198 PCr/US93/00082 22 addition of 30 ug of SDH and 32 P]-NAD to start the ADPribosylation reaction. At different time intervals, ul aliquots were removed and precipitated with TCA. A parallel control representing the same quantity of SDH and [32P]-NAD were incubated in the absence of sodium nitriprusside and aliquots were taken at the same time intervals as the test samples. Precipitated proteins were separated on SDS gel and autoradiographed. In a similar set of experiments, ADP-ribosylation was also performed using 200 ul of a streptococcal lysin extract in ADPR buffer incubated in the presence and absence of 2 mM sodium nitroprusside.
The results of the foregoing procedures are summarized below.
Purification of SDH protein receptor: SDH protein, was pr.ecipitated from the lysin extract by first precipitating non-specific proteins at saturation of ammonium sulfate followed by saturation. The SDH was found in the 85% ammonium sulfate precipitate (Fig. The dialyzed precipitate was applied to a Mono Q FPLC column and the proteins eluted with an NaCI gradient from 0 mM to 300 mM. SDH eluted at a salt concentration of about 280 mM.
Fractions with fibronectin binding activity were pooled, dialyzed and further purified on a Superose-12 FPLC molecular sieving column. The small amount of contaminating proteins was removed by hydrophobic chromatography using a TSK-phenyl column. SDS-PAGE of j the final preparation revealed a homogeneous protein with a molecular weight of 39 kDa. The total yield of purified protein from four liters of culture representing 6-8 gms wet weight of bacteria was 800 ug.
i iS :1 SWO 93/14198 PCr/US93/00082 24 other GAPDHs, sufficient differences were found that suggest that, except for the NH -terminal sequence, SDH is different from other reported GAPDHs.
GAPDH activity of SDH protein: In the presence of G-3-P in triethanolamine buffer at pl! 8.6, SDH showed a dose dependent conversion of NAD to NADH as observed by absorbance of the latter at 340 nm. Using 30 ug of purified SDH, variation of enzyme reaction rates with varying concentrations of G-3-P and NAD was determined. The results were analyzed both as Michaelis-Menten plots as well as double reciprocal plots according to Lineweaver-Burk (13) as shown in Figs. 3a and b. From these plots the Km for G-3-P and NAD was estimated to be 1.33 mM Vmax 0.487 X 10 3 M NADH min 1 Fig. 5 shows the analysis based on the method of -3 Michaelis-Menten. Km, 1.22 mM; and Vmax, 0.466 x 10 M NADH/min. 25 ug of the 39-kD protein was assayed as a function of NAD in the presence of G-3-P (2mM) in the buffer system described above. The Kr( for NAD was estimated to be 156.7 uM; Vmax, 0.459 x 10 3 M NADH/min; intercept on y-axis(1/Vmax), 2.18; and slope (Km/Vmax), 341.74 Km for NAD by the method of Michaelis-Menten as 1 shown in the inset was estimated to be 148.86 uM; and Vmax, 0.445 x 10 3 M NADH/min.
Determination of location of SDH on cell: Antibodies to SDH were affinity purified on SDHbound to activated gluteraldehyde beads followed by a protein A column. The resultant purified anti-SDH IgG recognized only the SDH protein band (Fig. Dot-Blot immunoassay was applied to determine the location of SDH on streptococcal surface. Results revealed that trypsin i WO 93/14198 PCT/US93/00082 treated streptococci were markedly reduced in their reactivity to anti-SDH IgG (Fig. To determine if the SDH protein is peripherally bound to the cell wal: or tightly bound, the streptococcal cells were washed with 2M NadC and 2% SDS. The results revealed that the SDK was not extractable by the high salt or ionic detergent.
Surface Enzyme activity of streptococci: To determine if the GAPDH enzymatic activity fouid with the purified SDH protein was also present on the streptococcal surface, enzymatic studies were carried c,ut using whole streptococci. The same concentration of substrates (G-3-P and NAD) used with the purified SDH were used with whole streptococci, Data presented In Fig. 6 revealed a dose dependent GAPDH activity catalyzed by the whole organisms. As found with the purified SDH, the intact bacteria also did not catalyze the reaction in absence of the specific substrates G-3-P and NAD (Fig. 6a). The enzymatic activity on the whole organisms was also found to be partially but specifically inhibitable by anti-SDH IgG (Fig. 6c). Enzymatic activity was found to be decreased by 80% when trypsinized bacteria were used in the reaction mixture (Fig. 6b). The background activity suggested an incomplete digestion of SDH protein by trypsin.
Prevalence of SDH protein in other M serotypes: The ubiquitous nature of the SDH protein in different streptococcal M serotypes was determined by Western blot analysis of lysin extracts using affinity purified anti-SDH IgG. As shown in Fig. 7, SDH protein
I.
SI
WO 93/14198 PCT/US93/00082 26 was found in several serotypes. Furthermore, all were found to be of same molecular weight without any indication of size variation.
Relationship of SDH with GAPDHs of bacterial, animal and human origin: The relationship of SDH with known GAPDHs was determined by both Western blot and competitive kinetic ELISA using affinity-purified anti-SDH antibodies.
Western blot (Fig. 8, insert) analysis with with SDHspecific antibodies revealed that GAPDH from bacillus, human RBCs, and rabbit muscle reacted weakly or not at all. This finding was further confirmed by competitoin ELISA (Fig. 8) showing that only a maximum of 20-25% inhibition of binding of anti-SDH antibodies to SHD could S 15 be achieved with 100 molar excess of these proteins, with the rabbit muscle GAPDH exhibiting the least activity.
The fact that almost 20% inhibition is observed with times molar excess of bacillus and human GAPDH may reflect the sequence homology observed at the NH 2 termini of these molecules (Fig. 2).
Binding property of SDH with lysozyme and cytoskeletal proteins: Since many glycolytic enzymes have been shown to bind cytoskeletal proteins a determination was made as to whether SDH has a similar property. 125I-SDH was used to probe a Western blot containing several cytoskeletal proteins. The results revealed that SDH binds to myosin and its globular domain (heavy meromyosin) and actin but not to the QL-helical domain of myosin (light meromyosin) or tropomyosin. (Figs. 9a and b) -1 WO 93/14198 PCT/US93/00082 27 Binding of fibronectin to the SDH protein: The fibronectin binding activity of SDH was determined both by using 25 I-labeled fibronectin or fibronectin-anti-fibronectin on a Western blot. The results revealed that the SDH protein was able to bind fibronectin in both assays (Figs. 10b and c).
Based on the results of all of the above, it has been determined that SDH is a major surface protein of streptococci, including group A streptococci and has both enzyme activity and multiple binding activity. No such protein has previously been detected, isolated and characterized. The novel surface protein is principally characterized by its ability to bind fibronectin, lysozyme and cycloskeletal protein as well as by its enzymatic activity as a GAPDH. Its molecular weight is approxitmptely 39 kDa. The first fifteen amino acid residues at the amino terminal are: Val-Val-Lys-Val-Gly-Ile-Asn-Gly-Arg-Ile-Gly-Arg-Leu -Ala-Phe These first fifteen amino acid residues manifest 100% homology with the bacterial form of GAPDH and 80-90% homology with eukaryotic or fungal GAPDH. SDH is, however, significantly different from previously recorpted GAPDHs, because the high homology of the first fifteen amino acid residues is not preserved towards the carboxy end of the molecule and the amino acid Scomposition varies appreciably from other GAPDHs.
SDH also functions as an ADP-ribosylating enzyme which, in the presence of NAD, is auto-ADP-ribosylated.
It has been found that in a crude lysin extract of group i SWO 93/14198 PCT/US93/00082 28 A streptococci containing a mixture of cell wall associated molecules, SDH is the only molecule that is ADP-ribosylated. Treatment of ADP-ribosylated SDH with the cytoplasmic fraction of Group A removed the ADPribosye of SDH which indicates the presence of SDH specific ADP-ribosyl hydrolase in the cytoplasmic compartment. Treatment of purified SDH or the crude lysin extract with sodium nitroprusside, which spontaneously generates nitric oxide, was found to stimulate the ADP-ribosylation of SDH in a time dependent manner. Both ADP-ribosylation and nitric oxide treatment inhibited the glyceraldehyde-3-phosphate dehydrogenase activity of SDH. In addition to its auto ADPribosylation activity, either purified SDH or whole streptococci with surface SDH were able to ADP-ribosylate specifically both chicken and human lysozyme, strong SDH binding proteins. These data show that SDH has both autoribosylation and ADP-ribosyl transferase activities.
SDH, as will be recognized by those skilled in the art, does not represent a single protien, but rather a class of surface proteins of streptococci, all of which have similar properties. The protein is involved in the colonization and probably in the internalization and proliferation of group A streptococci. One of the initial steps in the colonization of mucosal tissue by streptococci and subsequent infection by this bacteria, is the binding of the bacteria to fibronectin. Lysozyme is also believed to be involved in this binding step.
The enzyme activity of SDH may be involved in the <i 30 binding of the bacteria to endothelial cells by reaction of an aldehyde reduction product of teichoic acid which I 1 7
I
WO 93/14198 PCT/US93/00082 29 is a polyglycerol phosphate. The aldehyde function could bind the bacteria to the tissue surface by reaction with amino group on that surface.
Inhibition of this initial binding is, therefore, a major fuction in inhibiting or preventing streptococcal infection. Accordingly, antibodies to SDH which successfully compete with fibronectin and lysozyme for binding sites on the bacteria will inhibit the colonization of the pharyngeal mucosa by group A streptococci. Therefore the SDH and amino acid segments of the protein containing the appropriate antigenic determinants, for example those containing from about 6 to about 20 amino acid residues, are useful to inhibit streptococcal infection of mammals, including humans, by administering an amount of the selected product which will be effective to inhibit fibronectin binding and thereby inhibit colonization of the pharyngeal mucosa.
The proteins, polypeptides and peptides of this invention may be obtained by any of a number of known processes.
The protein can be isolated as described above.
Alternativley, the protein or segments thereof can be prepared by recombinant DNA techniques. For example, the gene for the protein or an oligonucleotide for the desired segment can be inserted into a plasmid and the plasmid used to transform E. coli so that the bacteria will express the desired product.
Polypeptide and peptides within the scope of the 4 invention containing, for example from about 6 to 20 or more amino acid segments, may be synthesized by standard solid phase procedures with appropriate amino acids using i ii :I -r WO 93/14198 PC/US93/00082 the protection, deprotection and cleavage techniques and reagents appropriate to each specific amino acid or peptide. A combination of manual and automated Applied Biosystem 430A) solid phase techniques can be used to synthesize the novel peptides of this invention.
Altough less convenient, classical methods of peptide synthesis can also be employed. For background on solid phase techniques, reference is made to Andreu, D., Merrifield, Steiner, H. and Boman, (1983) Proc. Natl. Acad. Sci USA 80, 6475-6479; Andreu, D., Merrifield, Steiner, H. and Boman, (1985) Biochemistry 24, 1683-1688; Fink, Boman, Boman, and Merrifield, (June 1989) Int. J. Peptide Protein Res. 33, 412-421; Fink, Merrifield, R.B., Boman, A. and Boman, (1989) J. Biol. Chem. 264- 6260-6267; each of which is hereby incorporated herein by reference.
The products of the invention are amphoteric. They can exist and be utilized as free bases or as pharmaceutically acceptable metallic or acid addition salts. Suitable metallic salts include alkali and alkaline earth metal salts, preferably sodium or potassium salts. Acid addition salts may be prepared from a wise variety of organic and inorganic acids including mineral acids, for example citric, lactic, maleic, tartaric, phosphoric and hydrochloric acids.
These salts can be prepared by procedures well known to those skilled in the art.
For use as a vaccine, it is presently preferred to administer the selected product conjugated to a carrier i such as cholera toxin B. Methods for preparing such L t WO 93/14198 PCr/US93/O0082 31 conjugates are known. One pr~cedure is described by Bessen and Fischetti Other carriers can be employed or the products can be used without a carrier.
The protein or segment thereof may also be administered as a hybrid protein expressed on a streptococcal surface utilizing the procedure of Pozzi et al (17,18).
Mice or other mammals including humans when immunized parenterally or orally have significant resistance to subsequent streptococcal challenges.
The presently preferred method for the administration of the vaccines of the invention is by the intranasal. route, but the invention is not so limited.
Other parenteral or oral prcoedures may be employed.
Typically, the patient to be protected will be treated with an amount of SDH or other product of the invention which is effective to elicit a protective immune response. The selected agent may be administered alone or in a pharmaceutically acceptable liquid or aolid carrier in which it may be dispersed, dissolved or suspended. If, for example, the patient is to be treated intravenously, the peptide may be suspended as a free base or dissolved as a metallic salt in isotonic aqueous buffer. Other methods of treatment and pharmaceutically acceptable carriers will be apparent to the skilled artisan. p The proteins, polypeptides and peptides of this invention and the genes or oligonucleotides which are employed in their expression are useful as probes for genes and proteins. They are also useful to raise WO 93/14198 WO 9314198PC/US93OOO82 antibodies by which specific strains of streptococci can be identified. For example in tests for mammalian infections.
I
J
I.
p
I:
U
I
WO 93/14198 PCr/US93/00082 33 TABLE 1 Comparison of Amino Acid Composition of SDH Protein from M Type 6 streptococci with That of GAPDH from Different Species No. of residues/mol SDH BSt Thaq RSM Amino Acid (36.0) (36.0) (34.0) Asn/ Asp Giu/ Gin Ser Gly His Arg Thr Ala Pro Tyr Val Met Ile Leu Phe Lys CyS Trp, 43.3 29.9 16.8 36.6 7.2 15.5 27.0 38. 1 13.6 9.1 36.5 1.8 22.4 23.*4 13.8 21.4 3.1S
ND
35.5 18.7 19 .7 31.7 9.8 10.1 21.6 32.*6 11.9 8.6 31.2 8.4 15.3 17.8 12 .9 23.*9
ND
Est, B. stearothermophilus Thaq, Thermus aquaticus RSH, Rabbit skeletal muscle *Mean of three determinations.
Molecular mass of SDH protein (35,882) was measured by I V WO 93/14198 PCT/US93/00082 34 laser desorption mass spectrometry.
S Determined by carboxy amidomethylation method The publications identified in this specification are all incorporated herein by reference.
REFERENCES
1. Wannamaker, L. W. 1973. The chains that link the throat to the heart. Circulation 48:9.
2. Pancholi, V. and V.A. Fischetti. 1989.
Identification of an endogeneous membrane anchor-cleaving I enzyme for group A streptococcal M protein. J. Exp. Med.
170:2119.
3. Pancholi, V. and V.A. Fishcetti. 1988. Isolation and characterization of the cell-associated region of group A streptococcal M6 protein. J. Bacteriol. 170:2618.
4. Matsudaira, P. 1987. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene 1 difluoride membranes. J. Biol. Chem. 262:10035.
Crestfield, S. Moore, and W.H. Stein. 1963.
The preparation and enzymatic hydrolysis of reduced and S. carboxymethylated proteins. J. Biol. Chem: 238:622.
6. Beavis, R.C. and B. T. Chait. 1990. High accuracy mass determination of proteins using matrix assisted laser desrrption mass spectrometry. Anal. Biochem.
62:1836.
7. Ferdinand, W. 1964. The isolation and specific activity of rabbit-muscle glyceraldehyde phosphate dehydrogenase. Biochem. J 92:578.
Si 1 L v 4( 1 1 l l 8. Horecker, B. L. and A. Kornberg. 1948. The extinction coefficient of the reduced band of pyridine nucleotides. J. Biol. Chem. 175:385.
9. Jones, K. F. and V.A. Fischetti. 1988. The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J. Exp. Med. 167:1114.
Jones, S.A. Khan, B.W. Erickson, S.K.
Hollingshead, J.R. Scott, and V.A. Fischetti. 1986.
Immunochemical localization and amino acid sequence of cross-reactive epitopes within the group A streptococcal M6 protein. J. Exp. Med. 164:1226.
11. Fischetti, V.A. and M. Windels. 1988. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule: Identification of an immunodominant region. J. Immunol. 141:3592.
12. Beavis, R.C. and B.T. Chait. 1990. Rapid, sensitive analysis of protein mixture by mass spectrometry. Proc.
Natl. Acad. Sci. U.S.A. 87:6873.
13. Lineweaver, H. and D. Burk. 1934. The determination of enzyme dissociation constants, J. Am. Chem. Soc.
56:658.
14. Bessen, D. and V.A. Fischetti. 1988. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect.
Immun. 56:2666. 141:3 Immun. 56:2666.i WO 93/14198 PCr/US93/00082 36 Kots, Skurat, Sergienko, E.A., Bulargina, T.V. Severin, E.S. (1992) FEBS Lett. 300, 9-12.
16. Pancholi, V. Fischetti, V.A. 1992. A Major Surface Protein On Group A Streptococci Is A Glyceraldehyde-3-Phosphate-Dehydrogenase with Multiple Binding Activity. J. Exp. Med. 176, 415-426.
17. Pozzi, M. Contorni, M.R. Oggioni, R. Hanganelli, M. Tommasino, F. Cavalieri, and V.A. Fischetti. 1992.
The delivery and expression of a heterologous antigen on the surface of streptococci. Infect. Immun. 60:1902- 1907.
18. Pozzi, M. Contorni, M.R. Oggioni, R. Manganelli, and V.A. Fischetti. 1992. Expression of M'6 protein gene of Streptococcus pyogenes in Streptococcus gordonii after chromosomal integration and transcriptional fusion. Res.
Microbiol. 143:449-457.
19. Harris, J.D. Hocking, M.J. Runswick, K.
Suzuki, and J.E. Walker. 1980. D-glyceraldehyde-3phosphate dehydrogenase: the purification and characterization of the enzyme from the thermophiles Bacillus stearothermophilus and Thermus aquaticus. Eur.
i J. Biochem. 108:535.
Caswell, and A.M. Corbett. 1985. Interaction of glyceraldehyde-3-phosphate dehydrogenase with isolated microsomal subfractions of skeletal muscle. J. Biol.
Chem. 260:6892.
lI IL 4:
Claims (5)
1. Streptococcal surface dehydrogenase and segments thereof capable of binding streptococci to fibronectin, lysozyme and cycloskeletal proteins, having glyceraldehyde-3-phosphate dehydrogenase activity, ADP- ribosylating activity and ADP-ribosyl transferase activity.
2. A vaccine effective to inhibit colonization of mucosal tissue by streptococci containing, together with a pharmaceutically acceptable carrier, a streptococcal surface iydr nase- or a segment thereof in an amount which is effective to inhibit said colonization, said hydrogenase being capable of binding streptococci ti fibronectin, lysozyme and cycloskeletal proteins, having glyceraldehyde-3-phosphate dehydrogenase activity, ADP- ribosylating activity and ADP-ribosyl transferase activity.
3. A method of treating a mammal to inhibit colonization of mucosal tissue by streptococci in a mammal in need of such inhibition which comprises deh roenase administration of a streptococcal surface -her-aFo.na.s or a segment thereof capable of binding streptococci to fibronectin, lysozyme and cycloskeletal proteins, having glyceraldehyde-3-phosphate dehydrogenase activity, ADP- ribosylating activity and ADP-ribosyl transferase activity in an amount sufficient to effect such inhibition.
4. A method of obtaining a streptococcal surface dehydrogenase which comprises solubilizing streptococci with lysin to produce a mixture containing the dehydrogenase and isolating the dehydrogenase from the J ~-now zr 38 mixture said dehydrogenase being capable of binding streptococci to fibronectin, lysozome and cycloskeletal proteins, having glyceraldehyde-3-phosphate dehydrogenase activity, ADP-ribosylating activity and ADP-ribosyl transferase activity, Streptococcal surface dehydrogenase and segments thereof, substantially as hereinbefo"e described with reference to any one of the Examples.
6. Streptococcal surface dehydrogenase, prepared by the method according to claim 4. Dated 19 March, 1996 The Rockefeller University Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON S S C I -t C S C CS C S C CCC C (C CC C C C I C ~CCC CCC' CC CC CC I C C C C C CCC C CSCC C C. CC CC CC C CC Ci (CCC CC C C CC iy~ [N:\LL3T]29396:.KEH
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81817092A | 1992-01-08 | 1992-01-08 | |
US91373292A | 1992-07-15 | 1992-07-15 | |
US913732 | 1992-07-15 | ||
PCT/US1993/000082 WO1993014198A1 (en) | 1992-01-08 | 1993-01-07 | Multifunctional surface protein of streptococci |
US818170 | 1997-03-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU3435193A AU3435193A (en) | 1993-08-03 |
AU668908B2 true AU668908B2 (en) | 1996-05-23 |
Family
ID=27124235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU34351/93A Ceased AU668908B2 (en) | 1992-01-08 | 1993-01-07 | Multifunctional surface protein of streptococci |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0672123A1 (en) |
JP (1) | JPH07502896A (en) |
AU (1) | AU668908B2 (en) |
CA (1) | CA2127550A1 (en) |
WO (1) | WO1993014198A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928900A (en) * | 1993-09-01 | 1999-07-27 | The Rockefeller University | Bacterial exported proteins and acellular vaccines based thereon |
TW448185B (en) * | 1993-11-05 | 2001-08-01 | Lilly Co Eli | Vaccine design and production |
US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US5846547A (en) * | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US6245335B1 (en) | 1996-05-01 | 2001-06-12 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US7217415B1 (en) * | 1998-12-22 | 2007-05-15 | Emergent Product Development Uk Limited | NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use |
NZ512297A (en) | 1998-12-22 | 2003-12-19 | Microscience Ltd | Genes and proteins of group a strep, and their use |
US6890539B2 (en) | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
US7256265B2 (en) | 1999-12-03 | 2007-08-14 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
ES2316450T3 (en) | 2000-06-12 | 2009-04-16 | University Of Saskatchewan | PROTEINA GAPC QUIMERICA DE STREPTOCOCCUS AND ITS USE IN VACCINATION AND DIAGNOSIS. |
BRPI0921286B8 (en) | 2008-11-05 | 2022-10-25 | Wyeth Llc | MULTIPLE COMPONENT IMMUNOGENIC COMPOSITION FOR THE PREVENTION OF BETA-HEMOLYTIC STREPTOCOCCAL (BHS) DISEASE. |
CN111198271B (en) * | 2018-11-16 | 2023-04-28 | 山东泽济生物科技有限公司 | Chemiluminescent enzyme-linked immunosorbent assay kit for detecting glyceraldehyde-3-phosphate dehydrogenase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5948490A (en) * | 1989-06-21 | 1991-01-08 | Rockefeller University, The | Recombinant poxvirus and streptococcal m protein vaccine |
-
1993
- 1993-01-07 JP JP5512544A patent/JPH07502896A/en active Pending
- 1993-01-07 WO PCT/US1993/000082 patent/WO1993014198A1/en not_active Application Discontinuation
- 1993-01-07 EP EP93902960A patent/EP0672123A1/en not_active Withdrawn
- 1993-01-07 AU AU34351/93A patent/AU668908B2/en not_active Ceased
- 1993-01-07 CA CA002127550A patent/CA2127550A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
ABS. AM. SOC. MICRO. 1991 VOL 91, NO B30 MOLECULAR MICROBIODOGY, 1991 VOL.5 NO.7. PP 1727-1734 * |
Also Published As
Publication number | Publication date |
---|---|
AU3435193A (en) | 1993-08-03 |
EP0672123A1 (en) | 1995-09-20 |
JPH07502896A (en) | 1995-03-30 |
WO1993014198A1 (en) | 1993-07-22 |
CA2127550A1 (en) | 1993-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Williamson et al. | A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene | |
AU668908B2 (en) | Multifunctional surface protein of streptococci | |
JP3816515B2 (en) | Cloning and recombinant production of wasp venom enzymes such as phospholipase and hyaluronidase and immunological treatment based on them | |
AU2340299A (en) | Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use | |
Marty et al. | Topography of the membrane-bound ADP/ATP carrier assessed by enzymic proteolysis | |
JPH03504077A (en) | ryegrass pollen allergen | |
JP3124753B2 (en) | Influenza vaccine and diagnostic methods | |
HU217582B (en) | Protein rib, a cell surface protein that confers immunity to strains of the group b streptococcus; process for purification of the protein; reagent kit, and pharmaceutical composition | |
Motin et al. | V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague | |
Karopoulos et al. | Antibody reactivity to mycobacterial 65 kDa heat shock protein: relevance to autoimmunity | |
IES76925B2 (en) | Subunit Vaccine for Streptococcus Equi | |
KR0170752B1 (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
JP3990730B2 (en) | Antigenic protein from Malassezia | |
US6869787B2 (en) | Ricin vaccine and methods of making and using thereof | |
US7108858B2 (en) | Non-anaphylactic forms of allergens and their use | |
JP2001515728A (en) | Stabilization of Helicobacter urease | |
EP0362274B1 (en) | Treatment and diagnosis of footrot using the basic protease of bacteroides nodosus | |
JP2011236217A (en) | NON-ANAPHYLACTIC FORMS OF GRASS POLLEN Phl p 6 ALLERGEN AND THEIR USE | |
EP1317484A2 (en) | Variants of phleum pratense allergenic proteins | |
CA2477094A1 (en) | Ricin vaccine and methods of making and using thereof | |
US20030049265A1 (en) | Heliobacter pylori antigen | |
JP3588615B2 (en) | Recombinant mite allergen | |
EP1465659A2 (en) | Use of a novel cell surface protease from group b streptococcus | |
Miura et al. | Identification of epitopes for cross-reaction, auto-reaction and autoantibodies to catalase | |
JP3983246B2 (en) | Antigenic protein from Malassezia |